Mr. Shah has over 25 years of experience in the pharmaceutical industry. He represents Alembic Pharmaceuticals Ltd (Alembic), an Indian-listed pharmaceutical company with a predominant presence in the Indian and US markets. He is responsible for Alembic’s international market strategy straddling generic and innovative products as well as external research partnerships. Prior to joining Alembic, Jesal led the institutional equity research group at JM Financial (2007-2013), a leading Indian investment banking firm. In this role, Jesal was responsible for providing research for the Indian pharmaceutical sector and other industry sectors in India. Previously, he was responsible for Indian healthcare research at JP Morgan (2004-2007) and was ranked as one of the top three analysts across multiple sectors in India and the best pharma analyst in Asia (ex-Japan). Prior to joining JP Morgan, Jesal worked with Dr. Reddy’s (2002-2004) in Portfolio Selection and SG Asia (2000-2002). He started his career with 20th Century Asset Management (1994-1999), a firm that was later acquired by HDFC Asset Management. Mr. Shah holds Master of Management Studies (MMS) degree from Mumbai University.